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Abstract
Background: Nucleic acid detection by polymerase chain reaction (PCR) is emerging as a sensitive and rapid diagnostic tool.
PCR assays on serum have the potential to be a practical diagnostic tool. However, PCR on bronchoalveolar lavage fluid
(BALF) has not been well established. We performed a systematic review of published studies to evaluate the diagnostic
accuracy of PCR assays on BALF for invasive aspergillosis (IA).
Methods: Relevant published studies were shortlisted to evaluate the quality of their methodologies. A bivariate regression
approach was used to calculate pooled values of the method sensitivity, specificity, and positive and negative likelihood
ratios. Hierarchical summary receiver operating characteristic curves were used to summarize overall performance. We
calculated the post-test probability to evaluate clinical usefulness. Potential heterogeneity among studies was explored by
subgroup analyses.
Results: Seventeen studies comprising 1191 at-risk patients were selected. The summary estimates of the BALF-PCR assay
for proven and probable IA were as follows: sensitivity, 0.91 (95% confidence interval (CI), 0.79–0.96); specificity, 0.92 (95%
CI, 0.87–0.96); positive likelihood ratio, 11.90 (95% CI, 6.80–20.80); and negative likelihood ratio, 0.10 (95% CI, 0.04–0.24).
Subgroup analyses showed that the performance of the PCR assay was influenced by PCR assay methodology, primer
design and the methods of cell wall disruption and DNA extraction.
Conclusions: PCR assay on BALF is highly accurate for diagnosing IA in immunocompromised patients and is likely to be a
useful diagnostic tool. However, further efforts towards devising a standard protocol are needed to enable formal validation
of BALF-PCR.
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Introduction
Invasive aspergillosis (IA) is the most common opportunistic
invasive fungal infection in immunocompromised patients,
especially those with prolonged neutropenia [1]. In patients with
hematological malignancies (HM), the prevalence of IA ranges
from 1–15% and mortality can reach as high as 90%, despite the
availability of several active antifungal agents [1].
Early diagnosis of IA remains a challenge, and few diagnostic
methods are available. The galactomannan (GM) assay may be
usefulinestablishing anearlierdiagnosisand mayresultinimproved
outcomes for immunocompromised patients [2,3]. The specificity of
GM detection in serum generally reaches over 90%. In broncho-
alveolar lavage fluid (BALF), GM detection can lead to an earlier
diagnosis of IA in patients with HM, yielding an increased sensitivity
when compared with serum, e.g., 85–100% versus 47% [4].
Molecular diagnostic techniques such as nucleic acid detection
by polymerase chain reaction (PCR) are emerging as potentially
more sensitive and rapid than conventional techniques for the
diagnosis of IA [5,6]. In addition to being helpful in IA diagnosis,
DNA amplification with an integrated system for species-level
identification based on melt-curve profiles or via an additional
probe, would be useful to save time and refine the diagnosis of
specific infections, allowing for administration of targeted
antifungal therapy based on species-level identification [7]. A
systematic review, which assessed the use of PCR on blood and
serum samples, showed its clinical value and recommended
standardization of PCR platforms [8].
BALF is routinely used to assess for the presence of fungi at the
site of pulmonary infection. Conventional microbiological tech-
niques like culture and histology of BALF are most commonly
used for the diagnosis of IA, but these techniques have suboptimal
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sensitivity and specificity. One review evaluated 15 clinical studies
investigating the diagnostic efficiency of performing PCR on the
BALF of IA patients and showed a promising clinical significance
although with some methodological limitations [10]. Using a
bivariate regression approach, we have now undertaken a
systematic review of all eligible, and more recent, clinical studies
to assess the accuracy of BALF-PCR as a diagnostic test for IA in
immunocompromised patients.
Materials and Methods
Two investigators searched MEDLINE and EMBASE for
relevant articles published up to December 2010 for Medical
Headings and text words that included the search terms
‘‘aspergillosis,’’ ‘‘aspergillus,’’ ‘‘polymerase chain reaction’’ and
‘‘bronchoalveolar lavage’’. The syntax for the MEDLINE searches
was as follows: ‘‘aspergillosis’’ OR ‘‘aspergillus’’ AND ‘‘polymerase
chain reaction’’ AND ‘‘bronchoalveolar lavage’’. The reference lists
of the included studies and review articles were also checked for
further relevant studies. Searches were restricted to English-
language literature on human subjects only; abstracts or meeting
proceedings were excluded. The results were then manually
searched for eligible studies. Full-text publications concerning
PCR on BALF were included if (1) they used the European
Organization of the Research and Treatment of Cancer/Mycoses
Study Group (EORTC/MSG) or the revised EORTC/MSG
criteria, as a reference standard [11,12], (2) for studies published
before the designation of these criteria in 2002, equivalent but non-
identical criteria were used as a reference standard, (3) the studies
reported the data separately on true-positive, false-positive, false-
negative, and true-negative results of the diagnostic tests, and (4) the
studies included immunocompromised or at-risk patients. To avoid
selectionbias,studieswith populationsfewerthan10wereexcluded.
Data extraction was performed independently by two reviewers
and any uncertainties or disagreements were resolved by
discussion. The quality of the selected studies was assessed as
recommended in the Standards for the Reporting of Diagnostic
Accuracy (STARD) by using 14 items of the Quality Assessment of
Diagnostic Accuracy Studies (QUADAS) lists [13,14].
Statistical analysis
To calculate test accuracy, we defined proven and probable
patients as having IA, and possible and no IA patients as not
having IA, to construct two-by-two tables, according to the revised
EORTC/MSG criteria [12]. We also constructed other two-by-
two tables (proven IA vs probable, possible, and no IA).
By undertaking a bivariate regression approach, we calculated
pooled estimates of sensitivity (SEN) and specificity (SPE) as the
main outcome measures, and constructed hierarchical summary
receiver operating characteristic (SROC) curves [15]. Based on
random-effects models, this bivariate approach investigates
potential between-study heterogeneity and incorporates the
possible correlation between the SEN and the SPE. Using the
pooled SEN and SPE, positive and negative likelihood ratios (PLR
and NLR, respectively) were also calculated.
Heterogeneity was assessed through the test of inconsistency (I
2)
of the pooled diagnostic odds ratios (DORs) [16]. DOR indicated
the accuracy of a diagnostic test, corresponding to particular
pairings of SEN and SPE. It illustrated the odds of positive test
results in participants with the disease compared with the odds of
positive results in those without the disease. The mean DOR was
used as an accuracy index and was performed by classic meta-
analytic pooling [17].
Potential heterogeneity was explored by subgroup analyses
[18,19]. Covariates clearly reported by more than 80% of studies
were analyzed: population (only HM vs. mixed/other), design
(cohort vs. case-control), data collection (prospective vs. retrospec-
tive), EORTC/MSG criteria (yes vs. no), PCR method (quanti-
tative vs. other), primer design (A.fumigatus-specific vs. other), cell
wall disruption method (commercial vs. ‘‘in house’’), and DNA
extraction method (commercial vs. ‘‘in house’’). Deeks’s funnel
plot was used to inspect publication bias [20]. Posttest probabil-
ity(PTP) was calculated by using the overall prevalence of 19%
with Fagan nomograms [21]. All analyses were performed using
STATA, version 10 (Stata Corp., College Station, TX) with the
module ‘‘Midas’’ [21]. All statistical tests were two sided, with P
values less than 0.05 denoting statistical significance.
Results
Our search criteria identified 2361 studies from literature. After
screening the titles and abstracts, 101 articles were selected for full-
text review and 84 studies were discarded for various reasons. In
two publications with suspected overlapping data from the same
medical services, we chose to include the larger of the studies
[22,23]. Ultimately, 17 studies with 1191 patients met the
inclusion criteria and were included in the systematic review
[23–39].
The characteristics of these studies are detailed in Table 1.
Overall, there were 1296 clinical BALF samples from 1191
patients. Most patients with HM received either chemotherapy or
a hematopoietic stem-cell transplant. The average prevalence of
proven and probable IA across cohort studies was 19% (range:
5.77–47.37%), which was higher than that reported in some
studies [3,40]. The relatively higher prevalence might result from
the different populations among these reviews. The participants of
the included studies mainly constituted patients with HM
accompanied by pulmonary infiltration.
Ten studies used the EORTC/MSG criteria, whereas seven
studies used similar criteria that were not identical to the
EORTC/MSG criteria. Three studies included eligible patients
exhibiting persistent fever who were unresponsive to first-line
broad-spectrum antibiotic treatment [25,27,35].
The details of the PCR techniques used are summarized in
Table 2. BALF was used in all studies (volume range: 0.1–5 ml).
Six studies used quantitative PCR (qPCR) in Aspergillus DNA
determination and the remainder used end-point PCR or semi-
quantitative PCR. The quality of all studies was generally high,
meeting on average 10 of the 14 QUADAS criteria (Fig. 1).
Data synthesis and metaanalysis
For all the studies, the pooled DOR was 122 (95% confidence
interval (CI) 41–363). Table 3 shows the SEN, SPE, PLR, NLR,
and DOR. The wide range of SEN was mainly because of the
variance of IA cases in different studies. We found substantial
heterogeneity among studies for all modalities because all I
2 values
were above 50%.
The SROC curve represents the relationship between SEN and
SPE across studies, determining the presence of a threshold effect.
Based on the bivariate approach which estimates not only the
strength but also the shape of the correlation between SEN and
SPE, a 95% confidence ellipse and a 95% prediction ellipse were
drawn(Fig. 2). The area under the SROC curve (AUC) was 0.97
(95% CI 0.95–0.98), signifying the high discriminatory ability of
BALF–PCR.
Subgroup analyses showed that the SEN of qPCR was
significantly lower than that of other types of PCR (Fig. 3). Studies
PCR on BALF for Diagnosis of Aspergillosis
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28467using commercial kits for cell wall disruption and DNA extraction
achieved significantly higher SPE than those using an ‘‘in house’’
method. These covariates did not affect the SEN yet. We also
found that using A.fumigatus species-specific primers led to a
significantly lower SPE than did using other primers (mostly
genus-specific primers).
Non-publication bias was detected by the Deek’s funnel plot
asymmetry test (P=0.55) [19]. The nomogram of Fagan
demonstrated that the PCR assay increased the probability of IA
nearly five-fold when the results were positive, and decreased the
probability to 1.5% when the results were negative (Fig. 4)[21].
Discussion
The frequency of IA has increased with the increasing number
of high-risk patients. The most common site of infection is
pulmonary and IA can easily disseminate to other organs [41].
Clinically, the gold standard for the diagnosis of IA still requires an
invasive procedure to provide histopathologic or cytopathologic
evidence. Unfortunately, the patient’s status often prohibits the use
of invasive techniques. Culturing of the causative agent can result
in false negative or false positive results. Bronchoscopy with BALF
seems to be a feasible diagnostic tool, with a high yield and low
complication rates [42–44].
Serum GM detection and PCR assays seem to have diagnostic
potential. Clinical trials have shown that GM assays on serum or
BALF and PCR assays on serum have variable performance in
different at-risk patient populations. The metaanalyses of Pfeiffer st
al. and Leeflang et al. both drew similar conclusion that serum
GM detection was moderately useful for diagnosing IA although
there were some methodological limitations in these studies [3,40].
In Leeflang et al.’s study, in which only proven and probable cases
were considered, the overall SEN increased by 17% (from 62% to
79%) with a decrease in the threshold from 1.5 to 0.5, and the
overall SPE decreased by 13% (from 95% to 82%). Mengoli et al.
determined the SEN and SPE of PCR for two consecutive positive
samples to be 0.75 and 0.87, respectively, and concluded that two
positive tests are required to confirm the diagnosis, whereas a
single PCR-negative result is sufficient to exclude a diagnosis of IA
[8]. Wang et al.’s found that, as a diagnostic tool, the BALF-GM
assay was better than serum GM detection [45]. This study
showed that the BALF-GM assay had a SEN of 0.90 and a SPE of
0.94 for proven and probable IA, which were both higher than the
corresponding values for the serum GM assay.
We undertook the present metaanalysis aiming to establish the
overall accuracy of the BALF-PCR assay for the diagnosis of IA
and to help standardize PCR assay and normalize clinical
performance. Our primary finding was that the BALF-PCR assay
is a powerful tool for the diagnosis of IA in patients with
hematological malignancy, and that the use of particular
procedures can improve diagnostic accuracy. However, the
increased SEN and SPE could be related to the high sensitivity
of PCR, and possible existing fungal colonization in the bronchial
tree of high-risk cases might contribute to the elevated SEN.
Comparing the diagnostic tools examined in all former metaana-
lyses, the BALF-PCR assay had the highest area under the SROC
Table 1. Characteristics of studies included in the analysis.
Study Study population
Age
group
Sample
processing
Study
design
Reference
standard
Radiology-
based BALF
Patients
(n)
Proven and
probable IA (n)
Bretagne 1995
24 HM, HIV NR Prospective Cohort Similar
1 NR 52 3
Buchheidt 2002
23 allogeneic HSCT, HM Adult Prospective Cohort Similar Y 141 26
Frealle 2009
25 HM Adult Retrospective Case-control EORTC/MSG NR 57 25
Hayette 2001
26 HM, SOC, CD NR Retrospective Cohort Similar NR 74 10
Jones 1998
27 HM NR Retrospective Case-control Similar NR 69 12
Khot 2008
28 HSCT, HM, pulmonary
infiltrates suggestive of
pneumonia
Adult Retrospective Cohort EORTC/MSG Y 81 13
Melchers 1994
29 HM Adult Retrospective Case-control EORTC/MSG NR 14 6
Musher 2004
30 HSCT NR Retrospective Case-control EORTC/MSG NR 93 46
Raad 2002
31 HM, SOC, pulmonary
infiltrates suggestive of
pneumonia
Adult Prospective Cohort EORTC/MSG NR 249 32
Rantakokko 2003
32 HM NR Retrospective Case-control EORTC/MSG NR 66 11
Sanguinetti 2003
33 HM, pulmonary infiltrates
suggestive of pneumonia
Adult Retrospective Cohort EORTC/MSG Y 44 20
Shahid 2008
34 BC Adult Retrospective Cohort EORTC/MSG Y 69 23
Skladny 1999
35 HM NR Retrospective Case-control EORTC/MSG Y 65 9
Spiess 2003
36 HM, pulmonary infiltrates
suggestive of pneumonia
NR Retrospective Case-control EORTC/MSG Y 31 11
Spreadbury 1993
37 HM,SOC Adult Retrospective Case-control Similar NR 16 3
Tang 1993
38 HM, BMT Adult Retrospective Case-control Similar NR 50 4
Verweij 1995
39 HM NR Retrospective Cohort Similar Y 19 9
1Studies that used criteria that were similar but not identical to the EORTC/MSG criteria.
Abbreviation: BALF, bronchoalveolar lavage fluid; BC, Bronchogenic carcinoma; BMT, bone marrow transplantation; CD, corticosteroid dependent; EORTC/MSG,
European Organization of the Research and Treatment of Cancer/Mycoses Study Group; HIV, human immunodeficiency virus; HM, hematological malignancy; HSCT,
hematopoietic stem-cell transplant; IA, invasive aspergillosis; NR, not reported; SOC, solid-organ cancer; Y, yes.
doi:10.1371/journal.pone.0028467.t001
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Study
BALF sample
volume(ml)
Sample
centrifugation
1
Cell wall
disruption
DNA extraction
methods
PCR experimental
method
Primer
design
Appropriate
controls
IAC
Extraction
controls
2
Bretagne 1995
24 1.5 NR SDS, proteinase Phenol-chloroform Competitive PCR A. fumigatus species Yes No
Buchheidt 2002
23 1.5 Yes Lyticase Phenol-chloroform Nested PCR Aspergillus species Yes Neg
Frealle 2009
25 0.2 Yes QIAamp DNA Mini Kit QIAamp qPCR A. fumigatus species Yes Pos/Neg
Hayette 2001
26 0.5 No SDS, proteinase Phenol-chloroform Nested PCR A. fumigatus and A.
flavus species
Yes No
Jones 1998
27 0.2 No SDS, proteinase Gentra pure PCR-ELISA Aspergillus species Yes Neg
Khot 2008
28 2–5 Yes MasterPure Yeast Kit MasterPure qPCR
3 Aspergillus species Yes Pos/Neg
Melchers 1994
29 NR Yes SDS, proteinase Phenol-chloroform End-point PCR Aspergillus species No Neg
Musher 2004
30 1.5 Yes MasterPure Yeast kit MasterPure qPCR Aspergillus species Yes Neg
Raad 2002
31 1 Yes SDS, proteinase Phenol-chloroform End-point PCR Aspergillus species Yes No
Rantakokko 2003
32 1.5 Yes SDS, proteinase Phenol-chloroform qPCR A. fumigatus species Yes No
Sanguinetti 2003
33 1.5 NR DNeasy Plant Mini Kit DNeasy qPCR
3 Aspergillus species No No
Shahid 2008
34 0.1 No SDS, proteinase Phenol-chloroform End-point PCR A. fumigatus, A. flavus
and A. niger species
No Neg
Skladny 1999
35 NR Yes SDS, proteinase Phenol-chloroform Nested PCR(two step) Aspergillus species Yes No
Spiess 2003
36 NR Yes SDS, proteinase Phenol-chloroform qPCR and nested
PCR
3,4
A. fumigatus species No Neg
Spreadbury 1993
37 0.25 No SDS, proteinase Phenol-chloroform End-point PCR A. fumigatus species Yes Neg
Tang 1993
38 0.25 No SDS, proteinase Phenol-chloroform End-point PCR A. fumigatus and A.
flavus species
No Neg
Verweij 1995
39 NR Yes SDS, proteinase Phenol-chloroform End-point PCR A. fumigatus species No Neg
1Studies that used a BALF pellet for detection after centrifugation.
2Positive or negative extraction control.
3Studies that quantified the fungal load in the BALF.
4Study
that used two PCR methods in the same population. Only the qPCR data are included.
Abbreviations: BALF, bronchoalveolar lavage fluid; ELISA, enzyme-linked immunosorbent assay; IAC, internal amplification control; Neg, negative; NR, not reported; PCR,
polymerase chain reaction; Pos, positive; qPCR, quantitative real-time PCR; SDS, sodium dodecyl sulphate buffer.
doi:10.1371/journal.pone.0028467.t002
Figure 1. Methodological quality graph of all 17 studies. Data are presented as a percentages bar across all included studies, according to the
Quality Assessment of Diagnostic Accuracy Studies lists.
doi:10.1371/journal.pone.0028467.g001
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tive ability.
We also investigated likelihood ratios, which take into account
the interaction between the SEN and the SPE in their calculation
and describe the discriminatory properties of positive and negative
test results. PLR .10 and NLR ,0.1 are usually considered
convincing evidence to rule in or rule out diagnoses, respectively
[46]. Although three metaanalyses did not report these results
[3,8,40], the conclusions of these studies suggested that serum GM
and serum PCR could not effectively discriminate IA. In our
metaanalysis, for proven and probable cases, the PLR and NLR
both exceeded the threshold index and generated large and often
conclusive shifts from pre-test to PTP.
It is an important objective of a metaanalysis to explore the
likely causes of heterogeneity [18,19]. In our subgroup analyses,
we identified several characteristics that might account for the
observed heterogeneity. The significantly lower SEN of qPCR
might be due to the use of a modified PCR assay for improvement
of SEN, such as nested PCR. Nested PCR formats have been
widely used for Aspergillus in an attempt to optimize analytical
sensitivity, but the requirement to open the reaction tubes means
that there is considerable risk of contamination and the subsequent
generation of false-positive results [47]. Recently, the real-time
quantitative format has become dominant in PCR-based diagnos-
tic studies of fungal infections [7]. The limit of its sensitivity was
found to be five copies of Aspergillus DNA per milliliter; this is
comparable to that of the commonly used nested PCR assay [48].
In addition, quantification of the fungal burden by real-time PCR
may be helpful to distinguish between colonization and infection,
and could possibly allow therapeutic monitoring [32]. Nowadays,
Figure 2. SROC curves from the bivariate model for proven and probable cases. The region enclosed by the dashed line (confidence
contour) contains likely combinations of the mean value of sensitivity and specificity. The region enclosed by the dotted line (prediction contour)
demonstrates more uncertainty as to where the likely values of sensitivity and specificity might occur for individual studies. SROC, summary receiver
operating characteristic.
doi:10.1371/journal.pone.0028467.g002
Table 3. Synthesized statistics with two definition criteria.
Patient definition Studies(n) DOR Pooled SEN Pooled SPE PLR NLR
Proven and probable versus
possible and no IA
17 122 (41–363)
1 0.91 (0.79–0.96) 0.92 (0.87–0.96) 11.9 (6.8–20.8) 0.10 (0.04–0.24)
Proven versus probable,
possible and no IA
8 49 (17–140) 0.90 (0.77–0.96) 0.84 (0.81–0.87) 5.7 (4.6–7.0) 0.12 (0.05–0.29)
1Values in parentheses are 95% confidence intervals.
Abbreviations: DOR, diagnostic odds ratio; IA, invasive aspergillosis; NLR, negative likelihood ratio; PLR, positive likelihood ratio; SEN, sensitivity; SPE, specificity.
doi:10.1371/journal.pone.0028467.t003
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application.
There is a multitude of fungal DNA extraction techniques. The
selected extraction method represents a compromise between
efficiency, freedom from exogenous contamination, and applica-
bility to routine high-throughput testing. The efficiency of
extraction of fungal DNA may vary considerably among
commercial kits [49], And this can hinder comparisons among
studies. We found that studies that used commercial kits for cell
wall disruption and DNA extraction achieved significantly higher
SPE than those that used ‘‘in-house’’ methods. The uniform
commercial kit for the GM assay contributes to its stable operation
and comprehensive use, and we believe that a uniform PCR assay
system may also promote the application of qPCR.
When designing primers for clinical diagnostic purposes, the
detection of a broad range of fungi is important, as is the ability to
increase SEN and ultimately identify the specific pathogen [50]. In
our study, we found that using A.fumigatus species-specific primers
led to a significantly lower SPE.of the use of narrow-spectrum
primers that does not lead to a lower SPE could be caused by poor
primer design. Some primers, which were designed based on
sequencing data that was not comprehensively validated, have
shown complementarity to the genomes of several other
microorganisms, such as Candida glabrata and Aspergillus oryzae
[24,32]. During primer design, it is necessary to conduct a
thorough in silico analysis based on multiple alignment of
validated sequences from various databases of as many Aspergillus
sequences as possible, plus human sequences and those of closely
related fungal pathogens such as Penicillium and Candida. Since
several species of Aspergillus are human pathogens, A.fumigatus
species-specific primers may lower the accuracy of PCR assays.
We recommend choosing Aspergillus genus-specific primers, to
improve PCR assay accuracy. The optimal approach, in this
regard, involves the application of genus-specific primers with
post-amplification analysis for species determination. Genus-
specific primers are directed toward conserved regions, usually
Figure 3. Forest plot of subgroup analyses for sensitivity and specificity. EORTC/MSG, similar to the European Organization of the Research
and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria 2008; Higher prevalence, prevalence above 23%; HM, hematologic malignancy;
Primer AF, A.fumigatus-specific primer; Commercial CWD, commercial kit for cell wall disruption; Commercial EX, commercial kit for DNA extraction;
* P,0.05; ** P,0.01; *** P,0.001.
doi:10.1371/journal.pone.0028467.g003
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specific polymorphisms that can be exploited in post-amplification
analysis [47]. However, Aspergillus genus-specific primers might
lead to a new problem. Penicillium, a genus phylogenetically close to
Aspergillus, has a high likelihood of cross reactivity within a PCR
assay, which might increase the false positive rate [6]. All primers
should be validated by a thorough in silico analysis using multiple
databases.
Another potential problem with PCR is sample contamination
from airborne particles. Fungal spores are ubiquitous in the
environment, and may cause false positive results in PCR.
Accordingly, measures to reduce exogenous fungal contamination
are critical [7]. A laminar flow hood in an independent laboratory
should be used exclusively for DNA extraction and pre-PCR
processing. Other measures to reduce contamination are a
unidirectional workflow pattern (pre- to post-PCR), physically
separating the laboratories for pre- and post-PCR analysis, and
using aerosol-resistant pipette tips and laminar flow hoods. In
addition, using the uracil-DNA glycosylase enzyme and dUTP
instead of dTTP in the PCR master mix can eliminate this
problem by destroying amplicons prior to PCR [7]. Moreover,
controls can be used to rigorously monitor contamination.
Negative control reactions, comprising all the PCR reagents
except the template DNA, are essential, and can be introduced at
any point in theassay, such as at sample acquisition, handling,
storage, and DNA extraction.
It is still difficult for BALF-PCR to distinguish colonization from
invasive infection. More importantly, the isolation of Aspergillus
from the respiratory tract should arouse vigilance, especially in
high-risk patients. The isolation of Aspergillus from the respiratory
tract may represent one of three scenarios: (1) evidence of current
disease, (2) true colonization, or (3) a marker for the probable
development of invasive disease. A previous study demonstrated
that a positive PCR result from BALF at the time of bone marrow
transplant conditioning was predictive of the subsequent develop-
ment of invasive pulmonary aspergillosis [51].
The PCR assay, especially qPCR, is becoming popular in the
clinical diagnosis ‘‘toolbox’’, such as for Pneumocystis pneumonia
diagnosis [52]. As the operation of PCR becomes more
automated, and extraction methods and targets become commer-
cially available, this tool should play an ever-greater role.
However, because at present most laboratories perform in-house
PCR assays, extensive validation and standardization is requied.
An initiative is currently in progress, to devise a standard for
Aspergillus PCR screening [8]. Once this has been achieved, formal
validation shoule be possible. As long as these standardized assays
are unavailable, a combination of various methods is still needed
to improve the accuracy of IA diagnosis of IA.
Our study had some limitations. First, we acknowledge that the
overall number of patients included in our review was relatively
small. Although we aimed to incorporate all available relevact
data, it is hard to ensure that no data were missed, especially
unpublished data. Second, we might have introduced bias by
exclusing non-English-language studies and studies with popula-
tion fewer than 10. To test the latter, we reanalyzed the data
including these small studies and obtained similar overall results.
Third, we used the revised EORTC/MSG criteria as a reference
standard which is widely accepted but not the ‘‘gold standard’’ for
diagnosis of every patient, especially for probable IA. The disease
group could be expanded when defining probable IA.
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